KDNY Historical Earnings image   This KDNY historical earnings page last updated 5/16/2022
KDNY Historical Revenue
PeriodHistorical Earnings DateGAAP
Q1 20225/12/20220.00B
Q4 20213/17/20220.05B
Q3 202111/8/20210.00M
Q2 20218/12/20210.03M
Q1 20215/12/20210.00B
Q4 20204/7/20210.00B
Q2 20208/3/20200.01B
Q1 20205/4/20200.01B
Q4 20193/9/20200.00B
Q3 201911/7/20190.00B
Q2 20198/1/20190.00B
Q1 20195/7/20190.00B
Q4 20182/27/20192.76M
Q3 201810/30/20183.06M
Q2 20188/1/20182.64M
Q1 20185/2/20186.63M
Q4 20173/1/20183.76M
Q3 201710/31/20173.79M
Q2 20178/2/20175.92M
Q1 20175/2/20173.77M
Q4 20163/1/20173.88M
Q3 201611/3/20163.79M
Q2 20168/3/201638.98M
Q1 20165/2/20164.03M
Q4 20153/8/201634.38M
Q3 201511/23/201519.15M
Q2 20158/10/20159.88M
Q1 20155/28/20159.57M
KDNY Historical Earnings EPS
Data adjusted for KDNY split history

PeriodHistorical Earnings DateGAAP
Q1 20225/12/2022-0.540
Q4 20213/17/20220.140
Q3 202111/8/2021-0.690
Q2 20218/12/2021-0.970
Q1 20215/12/2021-0.880
Q4 20204/7/2021-1.240
Q2 20208/3/2020-1.050
Q1 20205/4/2020-0.450
Q4 20193/9/2020-1.200
Q3 201911/7/2019-1.300
Q2 20198/1/2019-1.150
Q1 20195/7/2019-1.450
Q4 20182/27/2019-1.400
Q3 201810/30/2018-1.450
Q2 20188/1/2018-1.550
Q1 20185/2/2018-1.400
Q4 20173/1/2018-1.700
Q3 201710/31/2017-1.650
Q2 20178/2/2017-1.350
Q1 20175/2/2017-1.600
Q4 20163/1/2017-2.200
Q3 201611/3/2016-2.700
Q2 20168/3/20160.150
Q1 20165/2/2016-2.250
Q4 20153/8/20160.200
Q3 201511/23/20150.050
Q2 20158/10/2015-2.500
Q1 20155/28/2015-199.850
Quotes delayed 20 minutes

Email EnvelopeFree KDNY Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Chinook Therapeutics (KDNY) is categorized under the Healthcare sector; to help you further research past earnings across stocks, below are some other companies in the same sector:

KEQU Past Earnings
KIDS Past Earnings
KIN Past Earnings
KLDO Past Earnings
KMPH Past Earnings
KNTE Past Earnings
KOD Past Earnings
KPRX Past Earnings
KPTI Past Earnings
KRBP Past Earnings
What was the record high KDNY historical earnings result?
In terms of earnings or revenue, what is the best KDNY historical earnings result that Chinook Therapeutics has ever posted, and when?

✔️Accepted answer: Within our data set, the highest KDNY historical earnings result was set in Q4 2015, when Chinook Therapeutics posted results of 0.200/share. The most successful revenue quarter within our data set was Q4 2021 when Chinook Therapeutics reported revenue of 0.05B.

What was the lowest Chinook Therapeutics historical earnings result?
In terms of top line revenue or bottom line earnings per share, what was the lowest KDNY has reported, and when?

✔️Accepted answer: Within our data set, the lowest KDNY historical earnings result was set in Q1 2015, when Chinook Therapeutics posted results of -199.850/share. The smallest revenue quarter within our data set was Q3 2021 when Chinook Therapeutics reported revenue of 0.00M.

On this page we presented the KDNY historical earnings date information for Chinook Therapeutics. Reviewing that KDNY Historical Earnings for the company, we see that the highest historical earnings result in our data set was in Q4 2015, when KDNY posted gaap of 0.200/share. Meanwhile the lowest KDNY historical earnings result was in Q1 2015, when KDNY posted gaap of -199.850/share. Moving to Chinook Therapeuticss historical revenue numbers, the largest revenue quarter in our data set was seen in Q4 2021 when KDNY reported 0.05B in revenue, while the smallest revenue quarter was Q3 2021 when KDNY reported 0.00M in revenue.

For self directed investors doing their due diligence on KDNY or any other given stock, their research can benefit from looking into all of the Chinook Therapeutics historical earnings in our data set presented side by side on one page for ease of comparison. Reviewing this historical EPS information can help when projecting future earnings per share, as well as providing important context for pondering whether the historical earnings trajectory justifies the current stock value or not. That's why we bring you HistoricalEarnings.com to make it more convenient for investors to look into Chinook Therapeutics historical earnings, or the historical earnings information for any stock in our coverage universe. In your continued due diligence investigations, we hope you check out the further links included for historical PE studies, earnings surprises history as well as next earnings dates for KDNY. Thanks for visiting, and the next time you need to research KDNY historical earnings or those of another stock, we hope our site will come to your mind as your preferred historical earnings, revenue, and EPS research resource of choice.

Recommended: SLF Options Chain, AOA Dividend History, FDX MACD.

 

KDNY Historical Earnings | www.HistoricalEarnings.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalEarnings.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.